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Abstract
Introduction: The aim of this study was to establish adiponectin and resistin serum levels and their relationship with skeletal status in 
women from the RAC-OST-POL study. 
Material and methods: 40 women with the lowest and 40 women with the highest value of bone mineral density (BMD) measured at the 
femoral neck (FN) were selected from a total of 625 women after dividing them into six age categories. Mean age in the whole group of 
80 women was 66.1 ± 8.0 years. 22 women had osteoporotic fractures. Adiponectin and resistin were measured, and skeletal assessment 
included measurements of BMD of FN and total hip (TH) using Lunar DPX (USA) and quantitative ultrasound (QUS) of hand phalanges 
by means of DBM Sonic 1200 (IGEA, Italy). 
Results: Mean age did not differ between the subgroups, whereas height, weight, BMI and BMD were significantly higher in women with 
high BMD values. In women with high and low BMD, adiponectin concentration [µg/mL] was 24.81 ± 12.7 and 31.04 ± 12.64 respectively, 
and differed significantly (p < 0.05). Respective values for resistin concentration [ng/mL] were 3.29 ± 1.37 and 3.62 ± 1.45, and did not dif-
fer. Adiponectin negatively correlated with weight (r = –0.34, p < 0.01), BMI (r = –0.37, p < 0.01), FN BMD (r = –0.26, p < 0.05), TH BMD 
(r = –0.33, p < 0.01), and did not correlate with QUS result. Stepwise multiple regression analysis showed that TH BMD was negatively 
influenced by age and adiponectin and positively by weight, and that FN BMD was dependent on age and weight only. 
Conclusions: Our results suggest that adiponectin may be an independent factor influencing skeletal status in women aged over 55 years. 
(Endokrynol Pol 2012; 63 (6): 427–431)
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Streszczenie
Wstęp: Celem pracy było zbadanie stężeń adiponektyny i rezystyny w surowicy krwi kobiet uczestniczących w badaniu RAC-OST-POL 
oraz analiza wpływu tych substancji na stan szkieletu badanych. 
Materiał i metody: Spośród 625 uczestniczek badania RAC-OST-POL podzielonych na 6 kategorii wiekowych, wybrano 40 kobiet z naj-
niższymi i 40 kobiet z najwyższymi wartościami gęstości mineralnej kości (BMD) szyjki kości udowej (FN).
Średni wiek w całej grupie 80 kobiet wynosił 66,1 ± 8,0 lat. 22 kobiety przebyły uprzednio złamanie osteoporotyczne. Stężenia adiponektyny 
i rezystywny zostały oznaczone w surowicy, a ocena stanu szkieletu obejmowała zbadanie BMD szyjki kości udowej i całego bliższego 
końca kości udowej (TH) densytometrem Lunar DPX (USA) oraz ilościowe badanie ultradźwiękowe (QUS) paliczków ręki przy pomocy 
urządzenia DBM Sonic 1200 (IGEA, Włochy).
Wyniki: Średni wiek nie różnił się pomiędzy podgrupami, natomiast wzrost, masa ciała, BMI oraz BMD były znamiennie wyższe 
w podgrupie kobiet z wysokimi wartościami BMD. Stężenia adiponektyny [µg/mL] w podgrupach kobiet z wysoką i niską wartością BMD 
wynosiły odpowiednio 24,81 ± 12,7 and 31,04 ± 12,64 i różniły się znamiennie (p < 0,05). Analogiczne wartości dla rezystyny [ng/mL] 
wynosiły 3,29 ± 1,37 oraz 3,62 ± 1,45 i nie różniły się pomiędzy podgrupami. Stężenie adiponektyny korelowało negatywnie z masą ciała 
(r = –0,34, p < 0,01), BMI (r = –0,37, p < 0,01), FN BMD (r = –0,26, p < 0,05), TH BMD (r = –0,33, p < 0,01), nie korelowało natomiast 
z wynikami QUS. W analizie wielorakiej regresji krokowej wykazano istotny statystycznie wpływ wieku i stężenia adiponektyny (nega-
tywny) oraz masy ciała (pozytywny) na wartość TH BMD, podczas gdy FN BMD było zależne znamiennie jedynie od wieku i masy ciała.
Wniosek: Podsumowując, wyniki prezentowanego badania sugerują, że adiponektyna może być niezależnym czynnikiem determinującym 
stan szkieletu w grupie kobiet powyżej 55. roku życia. (Endokrynol Pol 2012; 63 (6): 427–431)
Słowa kluczowe: adiponektyna, gęstość mineralna kości, rezystyna
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Introduction
Osteoporosis is one of the commonest chronic diseases 
in elderly women. The most important consequence 
of osteoporosis is non-traumatic fracture, typically 
occurring at the forearm, spine, hip, arm and some-
times at other skeletal sites. Fracture risk depends on 
several factors including skeletal status and falls. One 
of many various factors influencing bone metabolism 
(e.g. endocrine system, diet, physical activity) is the 
amount of fat mass. Usually, obesity is considered to 
be protective against osteoporosis [1], and low body 
weight is considered to be a risk factor for osteoporosis 
and fracture [2, 3]. Fracture risk is inversely related to 
body mass index (BMI) and BMI plays an important 
role in the FRAX algorithm for establishing the fracture 
probability. Although much data indicates that adi-
pose tissue protects against osteoporosis, some recent 
studies have suggested that an increasing amount of 
fat may upgrade the fracture risk [4] and negatively 
affect bone status [5]. There are several mechanisms 
potentially linking fat and bone metabolism and 
skeletal status. Mechanical load connected with fat 
mass increases bone mass, but adipose tissue is also 
considered as an endocrine organ. Adipocytes produce 
not only oestrogen in postmenopausal women. Sev-
eral adipokines like leptin, adiponectin, resistin, and 
visfatin are produced in fat tissue [6, 7]. Adiponectin, 
exclusively expressed by adipocytes, circulates in much 
higher concentrations than other adipocyte products 
[8], and is inversely related to visceral fat mass and 
BMI [9]. As recently shown in a review by Biver at al. 
[8], consistent and inverse correlations between cir-
culating adiponectin levels and bone mineral density 
(BMD) at lumbar spine, total hip and total body in 
postmenopausal women have been found. Negative 
correlations between adiponectin and BMD remained 
significant even after adjusting for fat mass, BMI and 
body weight. 
The aim of the present study was to establish adi-
ponectin and resistin serum levels in women from the 
RAC-OST-POL study and to analyse their relationships 
with densitometric and quantitative ultrasound (QUS) 
measurements. 
Material and methods
Material
Women assessed in this study were recruited from 
the RAC-OST-POL study, which has been described 
previously [10]. Women enrolled into the RAC-OST-
POL project were randomly chosen from the general 
population aged 55 years or older in the district of Raci-
borz in southern Poland. The total number of women 
in the district was 57,357, and the total population of 
qualifiable women (i.e. those aged 55 years or over) 
inhabiting the region at the time of enrollment into the 
study was 17,500. 10% of that number (1,750 subjects) 
were randomly selected and invited by regular e-mail 
to participate in the study. A group of 625 women re-
sponded positively to the invitation and declared their 
intention to take part in the study, which was performed 
in May 2010. In order to perform the currently presented 
analysis, the whole RAC-OST-POL study group (n = 
= 625) was divided into six age categories (55–59, 60–64, 
65–69, 70–74, 75–79 and 80+). From each subgroup, 
the subjects with the lowest (n = 40) and highest 
(n = 40) values of femoral neck BMD were selected 
for analysis. Such selection allowed us to maintain the 
representativeness in the whole age range, as age is an 
important factor influencing bone status. The clinical 
characteristics of patients in the studied group (the 
whole group and subgroups with high and low BMD) 
are set out in Table I. 
Questionnaire
Each woman completed a questionnaire providing data 
on clinical risk factors for osteoporosis (prior fracture, 
family history of hip fracture, prolonged diseases, 
chronic medication, smoking, alcohol intake, falls). Only 
those fractures which had happened due to low-energy 
trauma resulting from a fall from a standing position or 
an even lower height and which had occurred after the 
age of 40 were considered as osteoporotic fractures for 
further analyses. Only falls in the previous 12 months 
were considered. The questionnaire was validated 
and qualified as an important source of input data. In 
women with high BMD, nine fractures were noted and 
in women with low BMD, 13 fractures were recorded. 
Forearm fractures were the most frequent. 
Fracture probability
Ten-year hip and any fracture probability was estab-
lished using a FRAX on-line calculator for the Polish 
population.
Bone densitometry
Skeletal status was assessed by bone densitometry on 
a Lunar DPX (GE, USA) and non-dominant femoral neck 
(FN) and total hip (TH) were evaluated. Densitometric 
variables were presented as BMD [g/cm2], T-score (the 
number of standard deviations [SD] from young adults) 
and Z-score (the number of SD from age-matched sub-
jects). All the measurements were performed by one 
operator. The coefficient of variation (CV%) was 1.6% 
for FN and 0.82% for TH. CV% was calculated on the 
basis of 50 measurements (two for each of 25 patients 
with reposition).
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QUS bone measurements
 A DBM Sonic 1200 (IGEA, Italy) device was used in 
the study. Amplitude-dependent sound speed (Ad-SoS 
[m/s]) levels were measured at distal metaphyses of the 
proximal phalanges II –V of a hand, and the mean value 
of four fingers was then taken into further analysis. 
T-score and Z-score values were also calculated. CV% 
was 0.64% based on serial measurements in 15 subjects.
Laboratory assays
Serum levels of adiponectin were determined by the 
radioimmunoassay (RIA) method and serum concentra-
tions of resistin were assessed by enzyme-linked immu-
nosorbent assay (ELISA) using commercial assays (Linco 
Research, St. Louis, MO, USA). The measures were made 
at the immunology laboratory of the Endocrinology 
Department. The intra- and inter-assay CV were less 
than 10% across the range of measured results. 
The Ethics Committee at the Medical University of 
Silesia in Katowice, Poland, approved the study pro-
tocol. Each woman gave an informed written consent 
prior to participation.
Statistics
All calculations were done using the Microsoft Office 
Excel application and the Statistica program (StatSoft, 
Inc. 2008, Tulsa, OK, USA. STATISTICA, version 8.0, 
www.statsoft.com) run on a PC computer. Descriptive 
statistics for quantitative values were presented as mean 
values and SDs. The distribution of analysed data was 
checked by the Shapiro-Wilk test. Among statistical 
evaluations, the t-test for independent samples or the 
Mann-Whitney U-test was performed for the compari-
son of parameters between subgroups (in case of normal 
and abnormal distribution, respectively). 
Stepwise multiple regression analysis was per-
formed; FN BMD and TH BMD were regressed on age, 
weight, height and adiponectin. Correlation analysis 
was done by Pearson’s or Spearman’s correlation, 
whichever appropriate. All p values < 0.05 were con-
sidered statistically significant.
Results 
Adiponectin serum concentration [µg/mL] was 24.81 
± 12.7 and 31.04 ± 12.64 in subgroups with high and 
low BMD respectively, and differed significantly (p < 
< 0.05). Respective values for resistin serum concentra-
tion [ng/mL] were 3.29 ± 1.37 and 3.62 ± 1.45, and did 
not differ. As one would expect, BMD, T-score, Z-score 
and fracture probability differed in subgroups with high 
and low BMD (Table II). Due to differences in mean 
age, we provided comparisons only for Z-scores for 
FN and TH BMD and Z-score for Ad-SoS. Adiponectin 
and resistin levels did not correlate significantly with 
fracture probability.
Resistin concentration did not correlate with BMD 
variables and body size. In the whole group, adiponec-
tin concentration negatively correlated with weight (r 
= –0.34, p < 0.01), BMI (r = –0.37, p < 0.01), FN BMD 
(r = –0.26, p < 0.05) and TH BMD (r = –0.33, p < 0.01). 
Figure 1 shows a relationship between adiponectin 
concentration and FN or TH BMD. FN and TH BMD 
correlated with Ad-SoS with r values of 0.4 and 0.38 (p < 
< 0.001), respectively. However, Ad-SoS did not cor-
relate with adiponectin and resistin levels. 
Stepwise multiple regression analysis showed that 
TH BMD was negatively influenced by age and adi-
ponectin and positively by weight, and that FN BMD 
was dependent on age and weight only. The following 
equations were obtained: 
FN BMD [g/cm2] = 0.598 [g/cm2] + 0.009 ¥ weight 
[kg] – 0.006 ¥ age [years], R2 = 0.4, SEE = 0.191, p < 
< 0.00001, 
Table I. Clinical characteristics of studied women (mean, SD)
Tabela I. Charakterystyka kliniczna kobiet uczestniczących w badaniu (wartości średnie, SD)
Parameter All women 
(n = 80)
Subgroup 
with high BMD (n = 40)
Subgroup 
with low BMD (n = 40)
Age (years) 66.1 ± 8.0 65.7 ± 8.1 66.4 ± 8.0
Height [cm] 155.8 ± 6.3 *157.6 ± 5.3 153.9 ± 5.4
Weight [kg] 76.9 ± 18.4 **88.0 ± 14.3 65.8 ± 15.1
Body mass index [kg/m2] 31.6 ± 7.2 **35.4 ± 5.5 27.9 ± 6.7
Menarche (year) 13.8 ± 1.7 14.1 ± 1.6 13.6 ± 1.71
Menopause (year) 48.4 ± 4.8 ***49.6 ± 5.0 47.1 ± 4.3
*significantly higher than in subgroup with low BMD, p < 0.01 
**significantly higher than in subgroup with low BMD, p < 0.0001 
***significantly higher than in subgroup with low BMD, p < 0.05
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TH BMD [g/cm2] = 0.683 [g/cm2] + 0.009 ¥ weight 
[kg] –0.005 ¥ age [years] –0.0025 ¥ adiponectin [µg/ 
/mL], R2 = 0.47, SEE = 0.184, p < 0.00001. 
Adiponectin levels in fractured and non-fractured 
women were 28.2 ± 14.0 and 26.6 ± 9.8 respectively, 
and did not differ.
Discussion
In the current study, we have shown that adiponectin, 
but not resistin, influences bone status assessed by den-
sitometric measurements of the proximal femur. We did 
not observe relationships between QUS parameter and 
adiponectin or resistin serum levels. To the best of our 
knowledge, ours is the first assessment of bone QUS 
in relation to adiponectin and resistin published in the 
medical literature. Our observations are consistent with 
data concerning the association of serum adiponectin 
with skeletal status evaluated by DXA given by some 
other authors [11–16]. In 36 postmenopausal women, 
adiponectin concentration correlated negatively with 
FN and TH BMD with r values of -0.45 and -0.46, respec-
tively [11]. In 232 patients, TH BMD correlated nega-
tively with r value of –0.26 [12] and other investigators 
[13] noted comparable results with regard to FN BMD 
(r = –0.24). Also, other authors have observed inverse rela-
tionships between BMD and serum level of adiponectin 
in women [14–16]. Generally, coefficients of correlation 
obtained in the current study were comparable with 
the results of other authors. The important results were 
shown by regression analysis; adiponectin remained 
a factor influencing bone variables only for TH BMD. 
Total hip consists of both cortical (mainly) and trabecu-
lar bone, and femoral neck and proximal diaphyses of 
hand phalanges contain almost only cortical bone. Also 
correlation analysis showed a slightly stronger relation-
ship of adiponectin concentration with TH BMD than 
with FN BMD. We presume that adiponectin affects 
mainly trabecular bone, but further investigations are 
necessary. On the other hand, Koroglu et al. did not 
find a correlation between adiponectin levels and BMD 
values measured at spine and hip in a group of diabetic 
postmenopausal women [17].
One may expect that a negative relationship be-
tween adiponectin level and bone densitometry values 
should be followed by significant differences between 
osteoporotic and non-osteoporotic patients. In our 
Figure 1. Relationships between adiponectin concentration and 
BMD values measured at femoral neck or total hip region
Rycina 1. Zależność pomiędzy stężeniem adiponektyny a 
wartością BMD szyjki kości udowej i końca bliższego kości udowej
Table II. Densitometric variables and fracture probability in subgroups
Tabela II. Wyniki badania densytometrycznego i prawdopodobieństwo złamań w badanych podgrupach
Parameter Subgroup 1 
with low BMD (n = 40) 
Subgroup 2 
with high BMD (n = 40)
FN BMD [g/cm2] 0.655 ± 0.053 1.124 ± 0.083
T-score –2.72 ± 0.38 0.62 ± 0.59
Z-score –1.2 ± 0.4 1.64 ± 0.51*
Total hip BMD [g/cm2] 0.741 ± 0.097 1.211 ± 0.086
T-score –2.13 ± 0.072 1.62 ± 0.086
Z-score –0.83 ± 0.69 2.13 ± 0.72*
FRAX — any fracture 11.1 ± 7.2 3.25 ± 1.77*
FRAX — hip fracture 5.5 ± 6.0 0.22 ± 0.43*
Ad-SoS [m/s] 1,937 ± 43 1,970 ± 59
T-score –3.7 ± 0.88 –3.04 ± 1.21
Z-score 0.31 ± 0.84 0.85 ± 1.1**
*significantly different than in subgroup 1, p < 0.00001 
**significantly different than in subgroup 1, p < 0.05
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study, we noted the expected significant difference in 
serum adiponectin between women with low and high 
BMD at the proximal femur. Other authors have failed 
to prove such differences [18–20]. Recently, important 
observations of BMD loss rates among 3,075 men and 
women aged 70–79 from the Health Ageing and Body 
Composition Study were published [21]. Among wom-
en, the annualised rate of hip areal BMD (aBMD) loss in 
the highest tertile of adiponectin was –0.67% (95% CI 
–0.77, –0.58) compared to –0.43% (95% CI –0.51, –0.35) 
in the lowest tertile (p trend = 0.019) after adjusting 
for age, race, BMI, diabetes, baseline hip aBMD and 
weight change. In men, hip aBMD loss was greatest 
in the high adiponectin group (tertile 3), although this 
association was not significant (p trend = 0.148). The 
authors concluded that serum adiponectin was associ-
ated with increased hip aBMD loss in women only, 
which provides supporting evidence that adiponectin 
may have an important role in bone health.
Some studies have assessed the association between 
adiponectin and the incidence of fractures [22–24]. In 
a 15-year follow-up of 507 men, no association between 
adiponectin and fractures was observed [22]. In an-
other study, the adiponectin level was independently 
associated with vertebral fractures in men, but in post-
menopausal women an analogous association for ver-
tebral and nonvertebral fractures did not occur [23]. In 
a prospective observation lasting 6.5 years of a cohort 
of 3,075 men and women aged 70–79 years, adiponectin 
was identified as a novel risk factor for fracture [24]. In 
the current study, we did not show a different level of 
adiponectin in regard to fracture status.
One should always take into consideration that both 
skeletal status and fat tissue hormones production are 
influenced by many cofactors, such as comorbidity [25]. 
As a result, the direct relation between fat and bone tis-
sue assessed by selective diagnostic tools may be quite 
often confounded in a specific group of patients.
Our study has several limitations: our group was 
relatively small (due to limited access to biochemi-
cal tests, we were not able to carry out our current 
study in the whole RAC-OST-POL study group but 
only in selected subjects); we did not observe them 
prospectively; and we chose only some women from 
a random, population-based cohort. In addition, the 
number of fractures was small, and bone densitom-
etry was limited to the proximal femur. It would be 
good to include quantitative ultrasound measure-
ments of skeletal sites rich in trabecular bone such 
as the calcaneus.
Our results suggest that adiponectin may be an in-
dependent factor influencing skeletal status in women 
aged over 55 years.
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